{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:44:09Z","timestamp":1783572249958,"version":"3.55.0"},"reference-count":136,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bleeding is a prevalent and frequently serious complication of anticoagulant therapy. The use of oral anticoagulants to prevent thrombotic events in common cardiovascular conditions, such as atrial fibrillation, exposes patients to an increased risk of bleeding which is associated with morbidity and mortality. The consequences of bleeding extend well beyond the acute event, affecting treatment adherence, long-term management decisions, and increasing the risk of ischaemic events when anticoagulation is discontinued. Optimizing the balance between thrombotic and bleeding risk requires expertise in risk stratification, preventive strategies, acute management, and the appropriate timing of anticoagulation resumption after haemostasis. This review summarizes the epidemiology and clinical impact of bleeding in patients receiving oral anticoagulant therapy and provides contemporary, patient-centred flowcharts for acute management and safe resumption of treatment. Future efforts should focus on refining risk prediction, individualizing anticoagulant regimens, and improving access to targeted reversal agents to further improve patient outcomes.<\/jats:p>","DOI":"10.1093\/ehjacc\/zuag035","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:38:49Z","timestamp":1773146329000},"page":"557-572","source":"Crossref","is-referenced-by-count":1,"title":["Managing bleeds on anticoagulant therapy: a practical guide for clinicians"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"first","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Corso della Repubblica, 79, Latina 04100 ,","place":["Italy"]},{"name":"Maria Cecilia Hospital, GVM Care & Research Department of Cardiology, , Cotignola 48033 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Simeone","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Corso della Repubblica, 79, Latina 04100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien","family":"ten Berg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, St.Antonius Hospital , Nieuwegein ,","place":["the Netherlands"]},{"name":"Maastricht Medical Centre Department of Cardiology, , Maastricht ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico Rodolico\u2014San Marco, University of Catania , Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, University of Italian Switzerland , Lugano ,","place":["Switzerland"]},{"name":"Department of Cardiology, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Sciarretta","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome , Corso della Repubblica, 79, Latina 04100 ,","place":["Italy"]},{"name":"IRCCS NeuroMed Department of Angiocardioneurology, , Pozzilli ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Greco","sequence":"additional","affiliation":[{"name":"Department of Health and Life Sciences, European University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4341-891X","authenticated-orcid":false,"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Herz- und Kreislauferkrankungen, TUM Klinikum Deutsches Herzzentrum, Technische Universit\u00e4t M\u00fcnchen , Munich ,","place":["Germany"]},{"name":"Deutsches Zentrum f\u00fcr Herz- und Kreislauf-Forschung (DZHK) e.V. (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[{"name":"ACTION Study Group, INSERM UMRS1166, Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP) , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"Baim Institute for Clinical Research, Harvard Medical School, Harvard University , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A","family":"Gorog","sequence":"additional","affiliation":[{"name":"University of Hertfordshire Department of Cardiology, , Hatfield, Hertfordshire ,","place":["UK"]},{"name":"National Heart and Lung Institute, Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , NewYork, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8451-2131","authenticated-orcid":false,"given":"Dominick J","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine , 655 West 8th Street\u2014Jacksonville, Jacksonville, FL 32209 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026070812124047100_zuag035-B1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026070812124047100_zuag035-B2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"2026070812124047100_zuag035-B3","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","article-title":"Antithrombotic therapy in high bleeding risk, Part I: percutaneous cardiac interventions","volume":"17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"2026070812124047100_zuag035-B4","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.jcin.2024.09.011","article-title":"Antithrombotic therapy in high bleeding risk, Part II: noncardiac percutaneous interventions","volume":"17","author":"Galli","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"2026070812124047100_zuag035-B5","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B6","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B7","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026070812124047100_zuag035-B8","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B9","doi-asserted-by":"crossref","first-page":"e004517","DOI":"10.1161\/JAHA.116.004517","article-title":"Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients","volume":"6","author":"Lamberts","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026070812124047100_zuag035-B10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026070812124047100_zuag035-B11","doi-asserted-by":"crossref","first-page":"e63479","DOI":"10.1371\/journal.pone.0063479","article-title":"Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry","volume":"8","author":"Kakkar","year":"2013","journal-title":"PLoS One"},{"key":"2026070812124047100_zuag035-B12","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026070812124047100_zuag035-B14","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MEG.0000000000002035","article-title":"Major gastrointestinal bleeding risk with direct oral anticoagulants: does type and dose matter?\u2014a systematic review and network meta-analysis","volume":"33","author":"Radadiya","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026070812124047100_zuag035-B15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/europace\/euz345","article-title":"Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention\/acute coronary syndrome patients","volume":"22","author":"Galli","year":"2020","journal-title":"Europace"},{"key":"2026070812124047100_zuag035-B16","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.31083\/j.rcm2308286","article-title":"Bleeding complications in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"2026070812124047100_zuag035-B19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","article-title":"Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention","volume":"151","author":"Gragnano","year":"2025","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B21","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/eurheartj\/ehp110","article-title":"Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial","volume":"30","author":"Mehran","year":"2009","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B22","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jacc.2013.11.029","article-title":"Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry use and light transmission aggregometry)","volume":"63","author":"Silvain","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026070812124047100_zuag035-B23","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1007\/s12325-025-03287-4","article-title":"Bleeding-related hospitalizations among direct oral anticoagulant users and nonusers in medicare fee-for-service: variation in prevalence, burden, and characteristics","volume":"42","author":"Bazell","year":"2025","journal-title":"Adv Ther"},{"key":"2026070812124047100_zuag035-B24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"2026070812124047100_zuag035-B25","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs-2022-0057","article-title":"Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Pharmacogenomics"},{"key":"2026070812124047100_zuag035-B27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ehjcvp\/pvad085","article-title":"Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026070812124047100_zuag035-B28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/ehjcvp\/pvaf034","article-title":"Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy","volume":"11","author":"Galli","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026070812124047100_zuag035-B29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf473","article-title":"Sex differences in dual antiplatelet therapy de-escalation strategies after percutaneous coronary intervention: a network meta-analysis","author":"Occhipinti","year":"2025","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11239-024-03022-w","article-title":"Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital","volume":"58","author":"Galli","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"2026070812124047100_zuag035-B31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026070812124047100_zuag035-B32","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O\u2019Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026070812124047100_zuag035-B34","doi-asserted-by":"crossref","first-page":"e017157","DOI":"10.1136\/bmjopen-2017-017157","article-title":"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation","volume":"7","author":"Fox","year":"2017","journal-title":"BMJ Open"},{"key":"2026070812124047100_zuag035-B35","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"2026070812124047100_zuag035-B38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4244\/EIJY14M06_07","article-title":"Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial","volume":"11","author":"Dewilde","year":"2015","journal-title":"EuroIntervention"},{"key":"2026070812124047100_zuag035-B40","first-page":"100524","article-title":"Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS\/PCI: a critical appraisal","volume":"28","author":"Galli","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026070812124047100_zuag035-B41","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great Debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week","volume":"43","author":"De Caterina","year":"2022","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ehjcvp\/pvz030","article-title":"Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy","volume":"6","author":"Galli","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026070812124047100_zuag035-B43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","article-title":"Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial","volume":"141","author":"Lopes","year":"2020","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B44","doi-asserted-by":"crossref","first-page":"975969","DOI":"10.3389\/fcvm.2022.975969","article-title":"De-escalation of antiplatelet therapy in acute coronary syndromes: why, how and when?","volume":"9","author":"Galli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026070812124047100_zuag035-B45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcin.2026.03.020","article-title":"Oral anticoagulation with or without antiplatelet therapy in chronic coronary syndrome: a meta-analysis of randomized trials","author":"Galli","year":"2026","journal-title":"JACC Cardiovasc Interv"},{"key":"2026070812124047100_zuag035-B46","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B47","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","article-title":"Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation","volume":"393","author":"Lemesle","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jama.2015.0809","article-title":"Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction","volume":"313","author":"Schjerning Olsen","year":"2015","journal-title":"JAMA"},{"key":"2026070812124047100_zuag035-B49","doi-asserted-by":"crossref","first-page":"e243208","DOI":"10.1001\/jamanetworkopen.2024.3208","article-title":"Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleeding","volume":"7","author":"Rahman","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026070812124047100_zuag035-B50","doi-asserted-by":"crossref","first-page":"e004587","DOI":"10.1136\/bmjopen-2013-004587","article-title":"Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis","volume":"4","author":"Narum","year":"2014","journal-title":"BMJ Open"},{"key":"2026070812124047100_zuag035-B51","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA"},{"key":"2026070812124047100_zuag035-B52","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B53","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026070812124047100_zuag035-B54","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.062","article-title":"Clinical effects of off-label reduced doses of direct oral anticoagulants: a systematic review and meta-analysis","volume":"362","author":"Pereira","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026070812124047100_zuag035-B55","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B56","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2026070812124047100_zuag035-B57","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026070812124047100_zuag035-B58","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B59","doi-asserted-by":"crossref","first-page":"n1205","DOI":"10.1136\/bmj.n1205","article-title":"Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial","volume":"373","author":"Kovacs","year":"2021","journal-title":"BMJ"},{"key":"2026070812124047100_zuag035-B60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B61","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann Intern Med"},{"key":"2026070812124047100_zuag035-B62","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2026070812124047100_zuag035-B63","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026070812124047100_zuag035-B64","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026070812124047100_zuag035-B65","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","article-title":"Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes","volume":"96","author":"Rao","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026070812124047100_zuag035-B66","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"GUSTO investigators","year":"1993","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B67","first-page":"234","article-title":"Clinical assessment of hemodynamically unstable patients","volume":"15","author":"Sevransky","year":"2009","journal-title":"Curr Opin Crit Care"},{"key":"2026070812124047100_zuag035-B68","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJMra1705649","article-title":"Hemorrhagic shock","volume":"378","author":"Cannon","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B69","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/EJA.0000000000001803","article-title":"Management of severe peri-operative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care: second update 2022","volume":"40","author":"Kietaibl","year":"2023","journal-title":"Eur J Anaesthesiol"},{"key":"2026070812124047100_zuag035-B70","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/jama.2016.9185","article-title":"Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage","volume":"316","author":"Carson","year":"2016","journal-title":"JAMA"},{"key":"2026070812124047100_zuag035-B71","doi-asserted-by":"crossref","first-page":"EVIDoa2400223","DOI":"10.1056\/EVIDoa2400223","article-title":"Restrictive versus liberal transfusion in myocardial infarction\u2014a patient-level meta-analysis","volume":"4","author":"Carson","year":"2025","journal-title":"NEJM Evid"},{"key":"2026070812124047100_zuag035-B72","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1056\/NEJMoa2307983","article-title":"Restrictive or liberal transfusion strategy in myocardial infarction and anemia","volume":"389","author":"Carson","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B73","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026070812124047100_zuag035-B74","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"2026070812124047100_zuag035-B75","first-page":"399","article-title":"The evaluation and management of coagulopathies in the intensive therapy units","volume":"12","author":"Galli","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026070812124047100_zuag035-B76","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B77","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"2026070812124047100_zuag035-B78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11239-015-1282-7","article-title":"Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication","volume":"41","author":"Cuker","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2026070812124047100_zuag035-B79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"2026070812124047100_zuag035-B80","first-page":"Cd000567","article-title":"Colloids versus crystalloids for fluid resuscitation in critically ill patients","volume":"2","author":"Perel","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070812124047100_zuag035-B81","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit Care"},{"key":"2026070812124047100_zuag035-B82","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"2026070812124047100_zuag035-B83","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.21469","article-title":"Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment","volume":"84","author":"Ageno","year":"2009","journal-title":"Am J Hematol"},{"key":"2026070812124047100_zuag035-B84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"key":"2026070812124047100_zuag035-B85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1211801","article-title":"Transfusion strategies for acute upper gastrointestinal bleeding","volume":"368","author":"Villanueva","year":"2013","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B86","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198301063080102","article-title":"Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia","volume":"308","author":"Mannucci","year":"1983","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B87","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tmrv.2014.03.002","article-title":"Hemostasis in liver disease: implications of new concepts for perioperative management","volume":"28","author":"Weeder","year":"2014","journal-title":"Transfus Med Rev"},{"key":"2026070812124047100_zuag035-B88","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/EJA.0000000000001968","article-title":"Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding","volume":"41","author":"Grottke","year":"2024","journal-title":"Eur J Anaesthesiol"},{"key":"2026070812124047100_zuag035-B89","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1055\/a-2464-2887","article-title":"Multidisciplinary expert guidance for the management of severe bleeding on oral anticoagulation: an algorithm for practicing clinicians","volume":"125","author":"Mithoowani","year":"2025","journal-title":"Thromb Haemost"},{"key":"2026070812124047100_zuag035-B90","doi-asserted-by":"crossref","first-page":"770","DOI":"10.5811\/westjem.2018.5.38235","article-title":"Emergency reversal of anticoagulation","volume":"20","author":"Yee","year":"2019","journal-title":"West J Emerg Med"},{"key":"2026070812124047100_zuag035-B91","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MBC.0b013e3283494b3c","article-title":"Protamine reversal of low molecular weight heparin: clinically effective?","volume":"22","author":"van Veen","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2026070812124047100_zuag035-B92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.thromres.2011.10.037","article-title":"Fondaparinux\u2014data on efficacy and safety in special situations","volume":"129","author":"Nagler","year":"2012","journal-title":"Thromb Res"},{"key":"2026070812124047100_zuag035-B93","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.thromres.2008.07.007","article-title":"Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC","volume":"123","author":"Desmurs-Clavel","year":"2009","journal-title":"Thromb Res"},{"key":"2026070812124047100_zuag035-B94","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"2026070812124047100_zuag035-B95","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","article-title":"Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial","volume":"385","author":"Goldstein","year":"2015","journal-title":"Lancet"},{"key":"2026070812124047100_zuag035-B96","doi-asserted-by":"crossref","first-page":"65s","DOI":"10.1111\/j.1537-2995.2012.03663.x","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"key":"2026070812124047100_zuag035-B97","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/acem.12911","article-title":"Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: an integrated analysis of two phase IIIb clinical trials","volume":"23","author":"Milling","year":"2016","journal-title":"Acad Emerg Med"},{"key":"2026070812124047100_zuag035-B98","first-page":"391","article-title":"Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis","volume":"166","author":"Dezee","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026070812124047100_zuag035-B99","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2001.03070.x","article-title":"A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin","volume":"115","author":"Watson","year":"2001","journal-title":"Br J Haematol"},{"key":"2026070812124047100_zuag035-B100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0039-1695771","article-title":"Global Use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program","volume":"120","author":"Fanikos","year":"2020","journal-title":"Thromb Haemost"},{"key":"2026070812124047100_zuag035-B101","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2026070812124047100_zuag035-B102","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B103","article-title":"Update on the Safety of Andexxa (andexanet alfa). FDA Safety Communication.","author":"US Food and Drug Administration (FDA)"},{"key":"2026070812124047100_zuag035-B104","author":"European Medicines Agency (EMA). Ondexxya (andexanet alfa): EPAR - Product information. Amsterdam: EMA"},{"key":"2026070812124047100_zuag035-B105","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"2026070812124047100_zuag035-B106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2020007116","article-title":"Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants","volume":"137","author":"Ansell","year":"2021","journal-title":"Blood"},{"key":"2026070812124047100_zuag035-B107","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B108","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026070812124047100_zuag035-B109","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition","volume":"27","author":"Rossaint","year":"2023","journal-title":"Crit Care"},{"key":"2026070812124047100_zuag035-B110","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1055\/a-1547-2282","article-title":"Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update","volume":"53","author":"Veitch","year":"2021","journal-title":"Endoscopy"},{"key":"2026070812124047100_zuag035-B111","doi-asserted-by":"crossref","first-page":"27377","DOI":"10.1038\/s41598-024-79133-4","article-title":"Transcatheter arterial embolization of nonvariceal gastrointestinal bleeding with n-butyl cyanoacrylate or coils: a systematic review and meta-analysis","volume":"14","author":"Matsumoto","year":"2024","journal-title":"Sci Rep"},{"key":"2026070812124047100_zuag035-B112","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2024.12708","article-title":"Perioperative management of patients taking direct oral anticoagulants: a review","volume":"332","author":"Douketis","year":"2024","journal-title":"JAMA"},{"key":"2026070812124047100_zuag035-B113","first-page":"S1","article-title":"Clinical practice guideline: nosebleed (epistaxis)","volume":"162","author":"Tunkel","year":"2020","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2026070812124047100_zuag035-B114","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1093\/eurheartj\/ehac587","article-title":"Bleeding and ischaemic events after first bleed in anticoagulated atrial fibrillation patients: risk and timing","volume":"43","author":"Meyre","year":"2022","journal-title":"Eur Heart J"},{"key":"2026070812124047100_zuag035-B115","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1055\/a-1400-6159","article-title":"Restart of anticoagulant therapy and risk of thrombosis, rebleeding, and death after factor Xa inhibitor reversal in major bleeding patients","volume":"121","author":"Milling","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026070812124047100_zuag035-B116","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1503\/cmaj.201433","article-title":"Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding","volume":"193","author":"Little","year":"2021","journal-title":"CMAJ"},{"key":"2026070812124047100_zuag035-B117","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archinternmed.2012.4261","article-title":"Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding","volume":"172","author":"Witt","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026070812124047100_zuag035-B118","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","article-title":"Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis","volume":"48","author":"Murthy","year":"2017","journal-title":"Stroke"},{"key":"2026070812124047100_zuag035-B119","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3390\/diagnostics15141780","article-title":"Antiplatelet resumption after intracerebral hemorrhage: a systematic review and meta-analysis","volume":"15","author":"Alharthi","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"2026070812124047100_zuag035-B120","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"2026070812124047100_zuag035-B121","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"The New England journal of medicine"},{"key":"2026070812124047100_zuag035-B122","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B123","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199802123380701","article-title":"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Pr\u00e9vention du Risque d\u2019Embolie Pulmonaire par Interruption Cave Study Group","volume":"338","author":"Decousus","year":"1998","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B124","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2015.3780","article-title":"Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial","volume":"313","author":"Mismetti","year":"2015","journal-title":"JAMA"},{"key":"2026070812124047100_zuag035-B125","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa2408308","article-title":"Left atrial appendage closure after ablation for atrial fibrillation","volume":"392","author":"Wazni","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070812124047100_zuag035-B126","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ahj.2022.05.001","article-title":"COMPARE LAAO: rationale and design of the randomized controlled trial \u201cCOMPARing effectiveness and safety of left atrial appendage occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy\u201d","volume":"250","author":"Huijboom","year":"2022","journal-title":"Am Heart J"},{"key":"2026070812124047100_zuag035-B127","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ahj.2021.08.020","article-title":"Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial","volume":"243","author":"Korsholm","year":"2022","journal-title":"Am Heart J"},{"key":"2026070812124047100_zuag035-B128","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association Between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"key":"2026070812124047100_zuag035-B129","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamainternmed.2021.1197","article-title":"Adverse Events associated with the addition of aspirin to direct oral anticoagulant therapy without a clear indication","volume":"181","author":"Schaefer","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2026070812124047100_zuag035-B130","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2026070812124047100_zuag035-B131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.11.014","article-title":"Gastroprotection in patients on antiplatelet and\/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)","volume":"85","author":"Abrignani","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2026070812124047100_zuag035-B132","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12471-018-1117-1","article-title":"A practical guide on how to handle patients with bleeding events while on oral antithrombotic treatment","volume":"26","author":"Gimbel","year":"2018","journal-title":"Neth Heart J"},{"key":"2026070812124047100_zuag035-B133","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1016\/j.jacc.2021.03.340","article-title":"Do we need to define therapeutic ranges for edoxaban plasma concentration?","volume":"77","author":"Cappannoli","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026070812124047100_zuag035-B134","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/ajg.2016.41","article-title":"ACG Clinical Guideline: management of patients with acute lower gastrointestinal bleeding","volume":"111","author":"Strate","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2026070812124047100_zuag035-B135","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/gutjnl-2018-317807","article-title":"Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology","volume":"68","author":"Oakland","year":"2019","journal-title":"Gut"},{"key":"2026070812124047100_zuag035-B136","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/ene.12429","article-title":"Low risk of late intracranial complications in mild traumatic brain injury patients using oral anticoagulation after an initial normal brain computed tomography scan: education instead of hospitalization","volume":"21","author":"Schoonman","year":"2014","journal-title":"Eur J Neurol"}],"container-title":["European Heart Journal: Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/advance-article-pdf\/doi\/10.1093\/ehjacc\/zuag035\/67317956\/zuag035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/7\/557\/67317956\/zuag035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/7\/557\/67317956\/zuag035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:13:03Z","timestamp":1783527183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/15\/7\/557\/8516524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":136,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuag035","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,12]]}}}